Introduction {#s1}
============

Loss-of-function mutations in *PARK2* and *PINK1*, which encode the cytosolic E3 ubiquitin ligase parkin and the mitochondrial ubiquitin kinase PINK1, respectively, are the most prevalent recessive causes of Parkinson's disease (PD), an age-dependent neurodegenerative disorder ([@bib12]). Parkin and PINK1 cooperate in the selective autophagic degradation of damaged mitochondria (mitophagy) ([@bib33]). Upon mitochondrial damage, PINK1 is stabilized on the outer mitochondrial membrane (OMM) and phosphorylates ubiquitin and parkin at their respective S65 residues. This activates parkin to catalyze ubiquitination of many OMM proteins that are then either degraded by the proteasome or act as signals for autophagic clearance of the mitochondrion ([@bib33]). Parkin-mediated mitochondrial ubiquitination and mitophagy are counteracted by specific deubiquitinases ([@bib3]; [@bib11]). PINK1/parkin-mediated mitophagy can be triggered in a variety of neuronal and non-neuronal cells in vitro, typically by exposure to mitochondrial depolarizing agents ([@bib27]; [@bib16]; [@bib8]; [@bib2]; [@bib11]; [@bib28]). Along with other mitochondrial quality control mechanisms PINK1/parkin-mediated mitophagy contributes to the maintenance of a healthy mitochondrial network ([@bib31]).

Despite the wealth of mechanistic information on PINK1/parkin-mediated mitophagy in cultured cells, questions still surround the existence and physiological relevance of this pathway in vivo ([@bib13]; [@bib43]). Direct evidence for the occurrence of PINK1/parkin-mediated mitophagy in vivo is still scarce. Ubiquitin phosphorylated at S65 (pS65-Ub), a biomarker of PINK1 activity, accumulates in brains from elderly human subjects ([@bib14]) and from mice with a genetic defect in mitochondrial DNA proofreading ([@bib32]), suggesting that PINK1-mediated mitophagy is induced by aging and accumulation of mitochondrial damage. However, a recent study reported that mitophagy occurs independently of PINK1 in the mouse ([@bib25]). In *Drosophila*, deficiency of PINK1 or parkin causes reduced life span and severe flight muscle degeneration with accumulation of swollen mitochondria ([@bib17]; [@bib30]; [@bib10]; [@bib29]). In parkin mutant flies, half-lives of mitochondrial proteins are drastically prolonged, consistent with a role for parkin in mitophagy, but the effect of PINK1 on mitochondrial protein turnover is much more limited ([@bib42]). Overall, it remains to be directly demonstrated whether PINK1 and parkin can target damaged mitochondria to lysosomes in vivo.

Recently, the mt-Keima reporter was developed to quantitatively image mitophagy in vitro and in vivo ([@bib21]; [@bib37]). Here, we used live mt-Keima imaging and correlative light and electron microscopy (CLEM) to assess mitophagy in *Drosophila* in vivo and to determine the role of parkin and PINK1 in this pathway.

Results {#s2}
=======

Mitophagy occurs in *Drosophila* flight muscle and increases with aging {#s2-1}
-----------------------------------------------------------------------

The phenotype of parkin- and PINK1-deficient flies is especially striking in flight muscle ([@bib17]; [@bib30]; [@bib10]; [@bib29]). We therefore focused on the role of mitophagy in this tissue. We generated flies that express mt-Keima specifically in muscle (*mef-2-Gal4*). The mt-Keima reporter is a mitochondrially targeted form of Keima, a fluorescent protein that resists degradation by lysosomal proteases ([@bib21]). The peak of the mt-Keima excitation spectrum shifts when mitochondria are delivered to acidic lysosomes, which allows dual-excitation ratiometric quantification of mitophagy ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). Transmission electron microscopy (TEM) analysis showed that mt-Keima expression did not change the morphology of muscle mitochondria ([Figure 1B](#fig1){ref-type="fig"}). The mt-Keima signal extensively colocalized with the mitochondrial protein ATP synthase β, confirming that mt-Keima was properly targeted to mitochondria ([Figure 1C](#fig1){ref-type="fig"}). Interestingly, a small subset of mt-Keima structures had high 543 nm/458 nm ratio values, indicative of an acidic environment ([Figure 1D](#fig1){ref-type="fig"}). These high 543/458 ratio mt-Keima puncta colocalized with the lysosomal dye LysoTracker ([Figure 1E](#fig1){ref-type="fig"}). Thus, the high 543/458 ratio mt-Keima puncta probably represented mitochondria that had been delivered to lysosomes. The abundance of these puncta was very low in muscle cells of 1-week-old adult flies, but strongly rose with aging, showing an approximately tenfold increase by the age of 4 weeks ([Figure 1F,G](#fig1){ref-type="fig"}). To assess the role of autophagy in the biogenesis of the high 543/458 ratio mt-Keima puncta, we overexpressed a kinase-dead version of Atg1 (Atg1^K38A^), the homologue of mammalian ULK1 ([@bib39]). Atg1/ULK1 is needed in the early steps of autophagosome formation and is also involved in mitophagy ([@bib20]; [@bib19]). When overexpressed, kinase-dead Atg1 exerts dominant-negative effects ([@bib35]). Overexpression of Atg1^K38A^ suppressed the high levels of mitophagy observed in aged muscle cells ([Figure 1F,G](#fig1){ref-type="fig"}). The low residual level of high 543/458 ratio mt-Keima puncta that persisted after Atg1^K38A^ overexpression, may result from Atg1-independent mechanisms of autophagy induction ([@bib6]).

![Mitophagy in *Drosophila* flight muscle increases with aging.\
(**A**) Schematic of mt-Keima imaging. The fluorescent mt-Keima protein is targeted to the mitochondrial matrix and exhibits pH-dependent excitation. The excitation peak of mt-Keima shifts from 440 nm to 586 nm when mitochondria are delivered to acidic lysosomes, where it resists degradation by lysosomal proteases. (**B**) Transmission electron micrographic images of mitochondria from control (*w^1118^;;)* and mt-Keima-expressing indirect flight muscle cells under control of the *mef-2-GAL4* driver (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+)*. Scale bar, 1 µm. (**C**) Confocal images of 1-week-old indirect flight muscle expressing mt-Keima under control of the *mef-2-GAL4* driver (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+)*. Images show mt-Keima emission at 543 nm excitation (Ex.) before and after fixation, immunostaining for ATP synthase β after fixation, and overlay. Scale bar, 10 µm. (**D**) Images of 1-week-old indirect flight muscle expressing mt-Keima under control of the *mef-2-GAL4* driver (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+)*. Images show live mt-Keima emission at 458 and 543 nm Ex., overlay of mt-Keima emissions at 458 and 543 nm Ex., and puncta with high 543 nm/458 nm ratio values. *Arrowheads* indicate examples of 'acidic' mt-Keima puncta. Scale bar, 10 µm. (**E**) Confocal images of mt-Keima-expressing indirect flight muscle labeled with LysoTracker (100 nM), showing colocalization of 'acidic' mt-Keima puncta with lysosomes (*arrowheads*). *Arrow* indicates an example of a lysosome devoid of mt-Keima signal. Scale bar, 10 µm. (**F**) Overlay of mt-Keima emission at Ex. 458 (green) and 543 nm (red) in *w^1118^* or Atg1^K38A^-overexpressing (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/UAS-Atg1^K38A^)* indirect flight muscle of 1-, 3- and 4-week-old flies. Scale bar, 10 µm. (**G**) High (543/458) ratio area/total mitochondrial area was quantified as an index of mitophagy (*n* = 4--6 flies per condition). In each fly, 7 random 2500 μm^2^ fields were analyzed. \*p=0.02 compared with all other conditions; \# p=0.02 compared with 1-week-old *w^1118^* flies.\
10.7554/eLife.35878.004Figure 1---source data 1.Quantification of mitophagy (high \[543/458\] ratio area/total mitochondrial area) in indirect flight muscle of *w^1118^* or Atg1^K38A^-overexpressing flies at 1, 3 and 4 weeks.](elife-35878-fig1){#fig1}

CLEM reveals the ultrastructure of 'acidic' mt-Keima puncta {#s2-2}
-----------------------------------------------------------

To demonstrate the occurrence of mitophagy in *Drosophila* indirect flight muscle more definitively, we resorted to CLEM ([@bib4]). We first performed live mt-Keima imaging of muscle cells to identify regions of interest that contained both 'acidic' and 'neutral pH' mt-Keima structures ([Figure 2A](#fig2){ref-type="fig"}). After fixation, we burned laser marks around the regions of interest using near-infrared branding (NIRB) to be able to re-identify these regions after processing for TEM ([Figure 2B--D](#fig2){ref-type="fig"}). Interestingly, 'neutral pH' mt-Keima structures colocalized with typical mitochondria at the TEM level, while 'acidic' mt-Keima puncta showed remarkable overlay with smaller organelles with the characteristic electron-dense appearance of lysosomes ([Figure 2E--N](#fig2){ref-type="fig"}). Many of the mt-Keima-positive lysosomes contained densely packed concentric membranes surrounding a dense core, giving them the appearance of multilamellar bodies ([Figure 2N](#fig2){ref-type="fig"}). Multilamellar bodies are lysosomal organelles that are found in various cell types in physiological conditions but also accumulate in lysosomal storage diseases ([@bib5]; [@bib18]; [@bib22]).

![Correlative light and electron microscopy (CLEM) reveals the ultrastructure of 'acidic' mt-Keima puncta.\
(**A--D**) Overview of the CLEM procedure from live mt-Keima imaging to EM. (**A**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) excitation (Ex.) in indirect flight muscle tissue of a 2-week-old control fly (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+*). Boxed area shows the region of interest (ROI) containing two high 543/458 ratio ('acidic') mt-Keima dots. (**B**) After fixation the same ROI as in (**A**) is re-identified based on muscle fiber morphology (mt-Keima emission at Ex. 543 nm). (**C**) Widefield image after near-infrared branding (NIRB) around the ROI (laser marks indicated by *arrowheads*). (**D**) EM image of the same ROI as in (**A--C**), surrounded by NIRB marks (indicated by *arrowheads*). (**E--H**) Magnification of the same ROI shown in (**A--D**). *Arrowheads* in (**E--H**) indicate 'acidic' mt-Keima dots that colocalize with lysosomes on EM. (**E**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) Ex. (**F**) High 543/458 ratio dots. (**G**) EM. (**H**) Overlay of EM and high 543/458 ratio mt-Keima image. (**I**) Further magnification of the boxed region in (**G--H**). (**J--N**) Additional CLEM example in muscle tissue of a 1-week-old control fly (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+*). *Arrowheads* in (**J--M**) indicate 'acidic' mt-Keima dots that colocalize with lysosomes on EM. (**J**) Live mt-Keima emission at 458 (green) and 543 nm (red) Ex. in muscle. (**K**) High 543/458 ratio dots. (**L**) EM. (**M**) Overlay of EM and high 543/458 ratio mt-Keima image. (**N**) Further magnification of the boxed region in (**L--M**). Scale bars in (**I**) and (**N**), 500 nm. All other scale bars, 5 µm.](elife-35878-fig2){#fig2}

Loss of Parkin and PINK1 impairs mitophagy in *Drosophila* flight muscle and dopaminergic neurons {#s2-3}
-------------------------------------------------------------------------------------------------

We then crossed the mt-Keima-expressing flies with *PINK1* loss-of-function mutant flies (*PINK1^B9^*) and *parkin* RNAi flies ([@bib29]; [@bib11]). The low level of mitophagy in 1-week-old adult flies was not affected by deficiency of PINK1 or parkin ([Figure 3A,B](#fig3){ref-type="fig"}). However, the age-dependent increase in mitophagy in 3- and 4-week-old control flies was completely abolished in the *PINK1^B9^* and *parkin* RNAi flies ([Figure 3A,B](#fig3){ref-type="fig"}).

![Deficiency of parkin and PINK1 impairs mitophagy in *Drosophila* flight muscle.\
(**A**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) excitation in indirect flight muscle from 4-week-old *w^1118^* (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/+)*, control (Ctrl) RNAi (*w^1118^; UAS-*Ctrl *RNAi/+; UAS-mt-Keima, mef-2-GAL4/+*), *PINK1^B9^* (PINK1^B9^/+;; *UAS-mt-Keima, mef-2-GAL4/+)* and *parkin1* RNAi *(w^1118^; UAS-parkin1 RNAi/+; UAS-mt-Keima, mef-2-GAL4/+)* flies. (**B**) High (543/458) ratio area/total mitochondrial area was quantified as an index of mitophagy in 1-, 3- and 4-week-old flies (*n* = 3--6 flies per condition). In each fly, 7 random 2500 μm^2^ fields were analyzed. \*p*=*0.02 compared with 4-week-old *parkin1* RNAi and *PINK1^B9^* flies. \# p*=*0.03 compared with 3-week-old *parkin1* RNAi and *PINK1^B9^* flies. (**C**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) excitation in indirect flight muscle from 4-week-old Ctrl RNAi (*w^1118^; UAS-*Ctrl *RNAi/+; UAS-mt-Keima, mef-2-GAL4/+*), *dUSP15* RNAi (*w^1118^;; UAS-mt-Keima, mef-2-GAL4/UAS-CG8334 RNAi), dUSP30* RNAi (*w^1118^; UAS-CG3016 RNAi/+; UAS-mt-Keima, mef-2-GAL4/+), parkin1* +Ctrl RNAi *(w^1118^; UAS-parkin1 RNAi/UAS-*Ctrl RNAi*; UAS-mt-Keima, mef-2-GAL4/+), parkin1 +dUSP15* RNAi (*w^1118^; UAS-parkin1 RNAi/+; UAS-mt-Keima, mef-2-GAL4/UAS-CG8334 RNAi), parkin1 +dUSP30* RNAi *(w^1118^; UAS-parkin1 RNAi/UAS-CG3016 RNAi; UAS-mt-Keima, mef-2-GAL4/+), parkin2* +Ctrl RNAi *(w^1118^; UAS-parkin2 RNAi/UAS-*Ctrl *RNAi; UAS-mt-Keima, mef-2-GAL4/+), parkin2 +dUSP15* RNAi (*w^1118^; UAS-parkin2 RNAi/+; UAS-mt-Keima, mef-2-GAL4/UAS-CG8334 RNAi), parkin2 +dUSP30* RNAi *(w^1118^; UAS-parkin2 RNAi/UAS-CG3016 RNAi; UAS-mt-Keima, mef-2-GAL4/+), PINK1^B9^*B9Ctrl RNAi (*PINK1^B9^*/+; *UAS-*Ctrl *RNAi*/+; *UAS-mt-Keima, mef-2-GAL4/+), PINK1^B9^ + dUSP15* RNAi (*PINK1^B9^*/+;; *UAS-mt-Keima, mef-2-GAL4/UAS-CG8334 RNAi)*, and *PINK1^B9^ + dUSP30* RNAi (*PINK1^B9^*/+; *UAS-CG3016 RNAi/+; UAS-mt-Keima, mef-2-GAL4/+)* flies. (**D**) High (543/458) ratio area/total mitochondrial area was quantified as an index of mitophagy (*n* = 3--4 flies per condition). \*p*\<*0.001 compared with Ctrl RNAi flies. \# p\<0.03 compared with *parkin1 +dUSP15* RNAi flies. £ p*\<*0.03 compared with *PINK1^B9^ + dUSP15* RNAi flies. Scale bars, 10 µm.\
10.7554/eLife.35878.007Figure 3---source data 1.Quantification of mitophagy (high \[543/458\] ratio area/total mitochondrial area) in indirect flight muscle of *w^1118^*, control RNAi, *PINK1^B9^* and *parkin1* RNAi flies at 1, 3 and 4 weeks.\
10.7554/eLife.35878.008Figure 3---source data 2.Quantification of mitophagy (high \[543/458\] ratio area/total mitochondrial area) in indirect flight muscle of 4-week-old control RNAi, *dUSP15* RNAi*, dUSP30* RNAi*, parkin1* + control RNAi*, parkin1 + dUSP15* RNAi, *parkin1 + dUSP30* RNAi*, parkin2* + control RNAi*, parkin2 + dUSP15* RNAi*, parkin2 + dUSP30* RNAi*, PINK1^B9^* +control RNAi*, PINK1^B9^ + dUSP15* RNAi, and *PINK1^B9^ + dUSP30* RNAi flies.](elife-35878-fig3){#fig3}

The DUBs USP15 and USP30 oppose parkin-mediated mitochondrial ubiquitination and mitophagy in cultured human cells. Interestingly, the yeast homologue of USP15 (Ubp12) deubiquitinates the MOM protein Fzo1, the yeast homologue of the mammalian parkin substrates mitofusin 1 and 2, pointing to a conserved role for USP15 in deubiquitination at the MOM ([@bib1]; [@bib36]). Knockdown of the *Drosophila* homologs of *USP15* (*CG8334*, hereafter called *dUSP15*) and *USP30* (*CG3016*, hereafter *dUSP30*) largely rescues the mitochondrial defects of parkin-deficient fly muscle in vivo ([@bib3]; [@bib11]). To assess the effects of dUSP15 and dUSP30 on PINK1/parkin-mediated mitophagy in vivo, we knocked down dUSP15 and dUSP30 in mt-Keima-expressing flies using RNAi. Levels of *dUSP15* mRNA in *dUSP15* RNAi lines were 57.6 ± 2.5% of control levels (*n* = 6), and *dUSP30* mRNA levels in *dUSP30* RNAi lines were 16.4 ± 5.8% of controls (*n* = 6). Knockdown of *dUSP15* and, to a lesser extent, *dUSP30* rescued the mitophagy defect of two different *parkin* RNAi fly lines ([Figure 3C,D](#fig3){ref-type="fig"}). The mitophagy defect of *PINK1^B9^* flies was partially rescued by *dUSP15* knockdown, but unaffected by *dUSP30* knockdown ([Figure 3C,D](#fig3){ref-type="fig"}).

Dopaminergic neurons of *parkin* mutant *Drosophila* also accumulate abnormal mitochondria ([@bib7]). We therefore expressed mt-Keima in dopaminergic neurons (*TH-GAL4*). As in muscle cells, mitophagy increased with aging ([Figure 4A,B](#fig4){ref-type="fig"}). Loss of parkin suppressed mitophagy in 4-week-old flies ([Figure 4A,B](#fig4){ref-type="fig"}), and this deficit was rescued by *dUSP15* knockdown ([Figure 4C,D](#fig4){ref-type="fig"}).

![Parkin deficiency impairs mitophagy in dopaminergic neurons.\
(**A**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) excitation in PPL1 dopaminergic neurons from 1- and 4-week-old control (Ctrl) RNAi (*w^1118^; UAS*-Ctrl *RNAi/+; UAS-mt-Keima, TH-GAL4/+)* and *parkin1* RNAi (*w^1118^; UAS-parkin1 RNAi/+; UAS-mt-Keima, TH-GAL4/+)* flies. (**B**) High (543/458) ratio area/total mitochondrial area was quantified as an index of mitophagy (*n* = 4 flies per condition). In each fly, 10 dopaminergic neurons were analyzed. \*p*=*0.001 compared with 4-week-old *parkin* RNAi flies. \# p*=*0.004 compared with 1-week-old Ctrl RNAi flies. (**C**) Overlay of live mt-Keima emission at 458 (green) and 543 nm (red) excitation in PPL1 dopaminergic neurons from 4-week-old Ctrl RNAi (*w^1118^; UAS*-Ctrl *RNAi/+; UAS-mt-Keima, TH-GAL4/+), dUSP15* RNAi (*w^1118^;; UAS-mt-Keima, TH-GAL4/UAS-CG8334 RNAi), parkin1* +Ctrl RNAi (*w^1118^; UAS-parkin1 RNAi/UAS-*Ctrl RNAi*; UAS-mt-Keima, TH-GAL4/+),* and *parkin1 +dUSP15* RNAi (*w^1118^; UAS-parkin1 RNAi/+; UAS-mt-Keima, mef-2-GAL4/UAS-CG8334 RNAi)* flies. (**D**) High (543/458) ratio area/total mitochondrial area in 4-week-old flies was quantified as an index of mitophagy (*n* = 3--4 flies per condition). \*p\<0.05 compared with all other conditions. Scale bars, 10 µm.\
10.7554/eLife.35878.010Figure 4---source data 1.Quantification of mitophagy (high \[543/458\] ratio area/total mitochondrial area) in PPL1 dopaminergic neurons from control RNAi and *parkin1* RNAi flies at 1 and 4 weeks.\
10.7554/eLife.35878.011Figure 4---source data 2.Quantification of mitophagy (high \[543/458\] ratio area/total mitochondrial area) in PPL1 dopaminergic neurons from 4-week-old control RNAi, *dUSP15* RNAi*, parkin1* +control RNAi, and *parkin1 +dUSP15* RNAi flies.](elife-35878-fig4){#fig4}

Discussion {#s3}
==========

Our data show that mitophagy occurs in *Drosophila* flight muscle and dopaminergic neurons in vivo, even in the absence of exogenous mitochondrial toxins. Mitophagy in these cells rises with aging, and this age-dependent increase is abrogated by PINK1 or parkin deficiency. Thus, PINK1 and parkin appear to be particularly important for mitophagy during aging, which may explain why loss of these proteins in patients causes an age-dependent neurodegenerative disease rather than a congenital or developmental disorder. Consistent with this, pS65-Ub, a readout of PINK1 activity, is almost undetectable in postmortem brains from neurologically normal, young human subjects, but accumulates in brains from elderly individuals ([@bib14]).

A recent study reported that PINK1 is dispensable for mitophagy in the mouse in vivo ([@bib25]). This conclusion was based on imaging using the *mito*-QC reporter, which differs from the mt-Keima probe used in our study. *mito*-QC is targeted to the OMM, whereas mt-Keima is localized to the mitochondrial matrix. Upon mitochondrial damage, activated parkin ubiquitinates a wide variety of OMM proteins, many of which are then extracted from the OMM and degraded by the proteasome before engulfment of the mitochondrion into an autophagosome ([@bib38]; [@bib9]; [@bib34]). The *mito*-QC probe consists of a tandem mCherry-GFP tag fused to a large portion of the OMM protein FIS1 ([@bib24]), which is itself a substrate of parkin ([@bib9]; [@bib34]). If *mito*-QC is ubiquitinated by parkin and extracted from the OMM, this would prevent *mito*-QC delivery to lysosomes and reduce its sensitivity as a reporter for PINK1/parkin-mediated mitophagy. An alternative explanation for the discrepant results could be that mice may not accumulate sufficient mitochondrial damage in their lifespan to activate PINK1/parkin-mediated mitophagy. The abundance of pS65-Ub in cerebral cortex is very low in wild-type mice, but is substantially higher in mice expressing a proof-reading-deficient version of mitochondrial DNA polymerase γ ([@bib32]). This suggests that a 'second hit' in addition to aging may be required to induce PINK1/parkin-mediated mitophagy in mice and may explain why PINK1 or parkin deficiency by itself does not cause a degenerative phenotype in this species.

In a recent *Drosophila* study Lee *et al.* were unable to detect mitophagy in flight muscle and found no evidence for a major role for PINK1 or parkin in mitophagy in other fly tissues ([@bib23]). The discrepancy with our correlative mt-Keima and TEM imaging findings may be due to the fact that Lee et al. mostly relied on imaging with *mito-*QC, a probe that may be less sensitive for parkin-mediated forms of mitophagy, as discussed above. Also, Lee *et al.* restricted their analysis of flight muscle to 2-day-old or younger flies, and may thus have missed the PINK1/parkin-dependent rise in mitophagy that occurs at later ages.

Recent publications proposed a distinction between basal and induced mitophagy ([@bib25]; [@bib23]). According to this terminology, the physiological mitophagy observed in our study could be labeled as basal. However, this may be confusing, because the term 'basal' suggests a relatively stationary background phenomenon, whereas our data show that 'basal' mitophagy in the fly is strongly induced by normal aging.

We did not detect a significant reduction in mitophagy in 1-week-old *PINK1^B9^* and *parkin* RNAi flies, at a time point when these flies already display mitochondrial abnormalities ([@bib17]; [@bib11]). This suggests that the mitochondrial changes in 1-week-old *PINK1^B9^* and *parkin* RNAi flies are caused by loss of aspects of PINK1 and parkin function that are unrelated to mitophagy. For example, parkin also regulates Ca^2+^ transfer from ER to mitochondria ([@bib15]). PINK1 promotes mitochondrial complex I activity through phosphorylation of the complex I subunit NdufA10 ([@bib26]) and is involved in crista junction remodeling via phosphorylation of dMIC60 ([@bib40]). Alternatively, the early mitochondrial abnormalities in PINK1- and parkin-deficient flies may be due to more subtle reductions in mitophagy that are not detectable with mt-Keima imaging.

Genetic manipulation in *Drosophila* is relatively straightforward. As illustrated by our *dUSP15* and *dUSP30* knockdown experiments, this novel mt-Keima fly model is a convenient tool to determine the impact of individual genes on PINK1/parkin-mediated mitophagy in vivo. This model will greatly facilitate the identification of targets for modulation of a pathway with growing relevance for neurodegenerative diseases.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation           Source or reference    Identifiers                                                                      Additional information
  or resource                                                                                                                                                
  ---------------------------- --------------------- ---------------------- -------------------------------------------------------------------------------- ----------------------------------------
  Strain (*D. melanogaster*)   *parkin* KK RNAi      VDRC                   107919\                                                                          Named *parkin2* RNAi\
                                                                            RRID:[FlyBase_FBst0476221](https://scicrunch.org/resolver/FlyBase_FBst0476221)   in this paper

  Strain (*D. melanogaster*)   *dUSP15* RNAi         VDRC                   18981\                                                                           
                                                                            RRID:[BDSC_61871](https://scicrunch.org/resolver/BDSC_61871)                     

  Strain (*D.* melanogaster)   *dUSP30* RNAi         NIG-Fly Stock Center   3016 R-2                                                                         

  Strain (*D. melanogaster*)   control TRiP RNAi     BDSC                   31603\                                                                           
                                                                            RRID:[BDSC_31603](https://scicrunch.org/resolver/BDSC_31603)                     

  Strain (*D. melanogaster*)   *parkin* TRiP RNAi    BDSC                   37509\                                                                           Named *parkin1* RNAi\
                                                                            RRID:[BDSC_37509](https://scicrunch.org/resolver/BDSC_37509)                     in this paper

  Strain (*D. melanogaster*)   *mef-2*-GAL4          BDSC                   27390\                                                                           
                                                                            RRID:[BDSC_27390](https://scicrunch.org/resolver/BDSC_27390)                     

  Strain (*D. melanogaster*)   *TH*-GAL4             BDSC                   8848\                                                                            
                                                                            RRID:[BDSC_8848](https://scicrunch.org/resolver/BDSC_8848)                       

  Strain (*D. melanogaster*)   *PINK1^B9^*           BDSC                   34749\                                                                           
                                                                            RRID:[BDSC_34749](https://scicrunch.org/resolver/BDSC_34749)                     

  Strain (*D. melanogaster*)   *Atg1^K38A^*          BDSC                   60736\                                                                           
                                                                            RRID:[BDSC_60736](https://scicrunch.org/resolver/BDSC_60736)                     

  Strain (*D. melanogaster*)   *VK20*                BDSC                   9738\                                                                            
                                                                            RRID:[BDSC_9738](https://scicrunch.org/resolver/BDSC_9738)                       

  Strain (*D. melanogaster*)   mt-Keima              This paper                                                                                              mt-Keima cDNA was cloned into\
                                                                                                                                                             the NotI and Xba1 sites of\
                                                                                                                                                             pUAS-attB and inserted in integration\
                                                                                                                                                             site VK20 after in-house injection

  Antibody                     ATP synthase β        Abcam                  ab14730\                                                                         1:500
                                                                            RRID:[AB_301438](https://scicrunch.org/resolver/AB_301438)                       

  Recombinant DNA reagent      mt/mKeima/pIND(SP1)   [@bib21]                                                                                                Gift from Dr. A. Miyawaki\
                                                                                                                                                             (RIKEN Brain Science Institute, Japan)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Drosophila* genetics {#s4-1}
---------------------

All *Drosophila melanogaster* stocks and experimental crosses were kept on standard corn meal and molasses food at room temperature. The mt-Keima construct (mt/mKeima/pIND(SP1)) was a gift from Dr. A. Miyawaki (RIKEN Brain Science Institute, Japan) ([@bib21]). The mt-Keima cDNA was cloned into the NotI and Xba1 sites of pUAS-attB and inserted in integration site VK20 after in-house injection. *CG8334* transgenic UAS-RNAi (18981) and *parkin* KK UAS-RNAi (107919, named *parkin2* RNAi in this paper) lines were obtained from the Vienna Stock Center (VDRC) and *CG3016* transgenic UAS-RNAi line (3016 R-2) from NIG-Fly Stock Center. Parkin (37509, named *parkin1* RNAi in this paper) and control (luciferase, 31603) TRiP UAS-RNAi lines, *mef-2-GAL4, TH-GAL4, PINK1^B9^ and Atg1^K38A^* were obtained from Bloomington stock center (Indiana, USA). To quantify *parkin*, *CG8334* and *CG3016* mRNA levels under control of *mef-2-GAL4*, RNA was isolated from adult thoraces and real-time RT-PCR was performed as previously described ([@bib11]) using primers 5'-CCAGCAATGTCACCATCAAAG-3' and 5'-GCGTGTCCACTCAGTCTG-3' for *parkin*, 5'-GGAGTGACGCATCTTGAG-3' and 5'-TTCTTTGGTATGGGTGGACTG-3' for *CG8334* and 5' TACGCCATAGCAATCTGGGG-3' and 5'- CTCGTGTATCTGCTGGCGTT-3' for *CG3016*. The data were normalized using *RP-49*, a ribosomal gene. Real-time PCR showed that *parkin* mRNA levels in *parkin1* RNAi flies were 49,7 ± 2,3% of control levels (*n* = 5). *Parkin* mRNA levels in *parkin2* RNAi flies were determined previously ([@bib11]).

Live mt-Keima imaging {#s4-2}
---------------------

Flies were dissected in HL3 buffer. Indirect flight muscle fibers and complete brains were immobilized on a glass slide in low gelling temperature agarose and analyzed using a Leica TCS SP5 II confocal microscope equipped with a 63x objective lens (HC PL APO 63x/1.4 CS2), a multi-argon laser (458, 476, 488 nm) and a He/Ne laser (543 nm). Mt-Keima was imaged in two channels via two sequential excitations (458 nm, green; 543 nm, red) and using a 600 to 695 nm emission range. Images from random microscopic fields were captured and analyzed by an investigator blinded to genotype and age. For muscle analysis, at least 7 z-stacks with 0.2 µm slice thickness were taken per fly. For dopaminergic neuron analysis, at least 10 PPL1 neurons were analyzed per fly. Ratio (543/458) images were created using the Ratio Plus plugin in ImageJ. High (543/458) ratio areas were segmented and quantified with the Analyze Particles plugin in ImageJ. The total mitochondrial area was quantified with the Analyze Particles plugin by calculating the area of the total emission at 543 nm excitation. The parameter (high \[543/458\] ratio area/total mitochondrial area) was used as an index of mitophagy, as described ([@bib21]). LysoTracker (DND-26, Thermo Fisher) was imaged using a 488 nm excitation and a 495--550 nm emission filter.

Immunohistochemistry {#s4-3}
--------------------

Indirect flight muscle was dissected in HL3, live imaged for mt-Keima and fixed in 4% paraformaldehyde for 1 hr. Samples were washed three times for 10 min in PBS and placed in blocking solution (5% normal donkey serum in PBS, 0.1% Triton X-100) for 30 min, after which the samples were incubated overnight at 4°C with antibody against ATP synthase β (1:500; ab14730, Abcam) in PBS, 2% normal donkey serum, 0.1% Triton X-100. After washing, samples were incubated for 2 hr with Alexa 488-conjugated secondary antibody in PBS, 2% normal donkey serum, 0.1% Triton X-100. Samples were washed and mounted on a glass slide in Vectashield mounting medium (Vector Laboratories). Alexa 488 fluorescence was imaged using a 488 nm excitation and a 495--550 nm emission filter.

CLEM {#s4-4}
----

CLEM studies using near-infrared branding (NIRB) were performed as described previously ([@bib4]; [@bib41]). Tissues were first imaged live in low gelling temperature agarose (3% in 0.1 M phosphate buffer, pH 7.4 \[PB\]), and fixed overnight in 0.5% glutaraldehyde, 4% PFA in 0.1 M PB, pH 7.4 at 4°C. Samples were rinsed in 0.1 M PB after which fixed samples were imaged using the Leica SP5 confocal microscope to check whether fixing affected overall tissue morphology. The bleaching function of the ZEN2010 software (Zeiss) was used to perform NIRB on a LSM 780 inverted confocal microscope. Branding marks were introduced to the tissue with a Mai Tai DeepSee two-photon laser (Spectra-Physics) at 800 nm and 40% maximal power output. Z-stacks of the region of interest were acquired before and after NIRB. Processed samples were post-fixed in 2% glutaraldehyde, 4% paraformaldehyde and 0.2% picric acid in 0.1 M PB at 4°C overnight or until further processing. Next, samples were osmicated for 1 hr in 2% OsO4, 1.5% potassium ferrocyanide in PB and subsequently stained for 30 min in 0.2% tannic acid, followed by overnight incubation in 0.5% uranyl acetate in 25% methanol. Next day, samples were stained *en bloc* with lead aspartate and dehydrated in an ascending series of ethanol solutions followed by flat embedding in Agar 100 (Laborimpex; Agar Scientific). Flat-embedded sections were mounted on aluminum pin stubs (Gatan) with conductive epoxy (Circuit Works). A Zeiss Sigma Variable pressure SBF-SEM with 3View technology (Gatan) was used to approach the region of interest. Imaging was done at 1.3 kV with a pixel size of 20 nm and sections of 200 nm. Regions of interest could be located based on the branding marks and muscle fiber morphology. When the region of interest was reached, 70 nm thick, serial ultrathin sections were cut using a Reichardt Ultracut E ultramicrotome. All sections were collected as ribbons of 4--5 sections on triple slot grids (Ted Pella). Images were taken on a JEOL JEM-1400 Transmission Electron Microscope operated at 80 kV.

Statistics {#s4-5}
----------

Values and error bars represent mean ± SEM, and *n* refers to the number of biological replicates. Significance of differences between conditions was analyzed with one-way ANOVA and post-hoc Holm-Sidak test (SigmaStat 3.5, Systat). No outliers were excluded.
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National Institute of Neurological Disorders and Stroke, National Institutes of Health

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Deficiency of parkin and PINK1 impairs age-dependent mitophagy in *Drosophila*\" for consideration by *eLife*. Your article has been favorably evaluated by Ivan Dikic (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript of Cornelissen et al. is an interesting, well-written, and well-developed study that addresses an important and controversial question: does the well-established pathway by which PINK1 and parkin can trigger mitophagy actually matter to neurons in vivo. Despite all the mechanistic analysis of this pathway in vitro, evidence of its importance in the normal context in vivo has been scarce and depended on the presence of additional stressors such as toxins or mutator strains. Negative results have been reported in the mouse and, very recently, in *Drosophila* as well. The present manuscript offers very persuasive data to say that it does function in vivo but only in aged animals, in this case *Drosophila*. Among the strong points of the manuscript are the care with which they have justified the use of their reporter, mito-Keima as a marker of mitochondria and, when the fluorescence ratio has shifted, as a marker of mitochondrial proteins or mitochondria-like structures in electron-dense lysosomes, including by CLEM. Other strong points include the use of a dominant negative ATG1 to show that this signal is autophagy driven, the use of DUB RNAi to confirm that the mitophagy is happening by the predicted mechanism of Parkin, clear statistical analysis and the inclusion of the actual P values, and a thoughtful discussion of why the other recent studies failed to see the change in mitophagy with PINK or Parkin mutants.

Essential revisions:

Two areas of concern were noted that require additional data.

1\) Figure 1C is problematic because of the spectral overlap of the fluorophores. Rather than the use of a second GFP reporter, an antibody to a mitochondrial protein should be used and then visualized with a fluorescent secondary antibody in a frequency range far from those of Keima.

2\) The section on the deubiquitinases needs strengthening. This needs the inclusion of a proper control UAS-construct to exclude the possibility that the UAS-USP15 and USP30 genes are not merely titrating GAL4 away from the UAS-Parkin RNAi. Inclusion of a Parkin hypomorphic mutation, rather than only the RNAi, and of a PINK1 allele in Figure 3C, D would also strengthen the analysis.

Additional concerns can be addressed in the text.

1\) A more detailed description of the image processing used throughout.

2\) The authors are commended for discussing the discrepancies between their study and that of Lee et al., but are not always accurate in describing that work. Among other things, they should clarify the distinction between basal and induced mitophagy.

3\) The authors should address the unlikely but formal possibility that increased Keima signal results from slower degradation of Keima in the mutants rather than increased mitophagy.
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Author response

> Essential revisions:
>
> Two areas of concern were noted that require additional data.
>
> 1\) Figure 1C is problematic because of the spectral overlap of the fluorophores. Rather than the use of a second GFP reporter, an antibody to a mitochondrial protein should be used and then visualized with a fluorescent secondary antibody in a frequency range far from those of Keima.

As requested by the reviewer, we have removed the mito-GFP data from the manuscript. We have now performed immunohistochemistry on indirect flight muscle using a primary antibody against the mitochondrial protein ATP synthase b and an Alexa 488-conjugated secondary antibody. In their original paper on Keima and mt-Keima imaging (Katayama et al., 2011) Katayama et al. demonstrate that the Keima and mt-Keima probes can be imaged simultaneously with the Alexa 488 fluorophore within the same cell without serious concerns for cross-excitation, cross-detection and resonance transfer (cfr. Figures S3, S4 and S5 in their paper).

Our experiments showed that the mt-Keima signal in flight muscle extensively colocalized with ATP synthase b, confirming that mt-Keima was properly targeted to mitochondria. We show these data in the new panel Figure 1C.

> 2\) The section on the deubiquitinases needs strengthening. This needs the inclusion of a proper control UAS-construct to exclude the possibility that the UAS-USP15 and USP30 genes are not merely titrating GAL4 away from the UAS-Parkin RNAi. Inclusion of a Parkin hypomorphic mutation, rather than only the RNAi, and of a PINK1 allele in Figure 3C, D would also strengthen the analysis.

\- We have now included proper control UAS constructs in Figure 3C-D and Figure 4C-D. The data show that there was no effect of "GAL4 dilution" and thus the conclusion of the experiment did not change.

\- In *Drosophila* the parkin gene is located on the third chromosome. Unfortunately, the *dUSP15* RNAi, *mef-2-GAL4* and mt-Keima transgenes are also located on the third chromosome. We were not able to recombine these 3 insertions with a hypomorphic parkin mutation (all 4 are on the third chromosome).

We nonetheless provide further support by instead including data obtained with an additional *parkin* RNAi line (*parkin* KK RNAi). In the new Figure 3C-D we show that knockdown of *dUSP15* and *dUSP30* rescues the mitophagy defect of 4-week-old flies that express *parkin* KK RNAi (similar to the rescue of flies expressing *parkin* TRiP RNAi).

As requested, we also included the *PINK1^B9^*flies in the section on the deubiquitinases. We found that knockdown of *dUSP15* partially rescued the mitophagy defect of 4-week-old *PINK1^B9^*flies, while knockdown of *dUSP30* had no effect. We have added these findings to Figure 3C-D.

> Additional concerns can be addressed in the text.
>
> 1\) A more detailed description of the image processing used throughout.

We have added more details on image processing to the Materials and methods (section 'Live mt-Keima imaging').

> 2\) The authors are commended for discussing the discrepancies between their study and that of Lee et al., but are not always accurate in describing that work. Among other things, they should clarify the distinction between basal and induced mitophagy.

We have revised our description of the study by Lee et al. so that the description is fully accurate.

Recent publications by Lee et al. (2018) and by McWilliams et al. (2018) indeed proposed a distinction between basal and induced mitophagy. According to this terminology, the physiological mitophagy observed in our study could probably be labeled as basal. However, this terminology may be confusing, because the term 'basal' suggests a relatively stationary background phenomenon, whereas our data show that 'basal' mitophagy in the fly is strongly induced by normal aging.

We have added these comments to the Discussion of the revised manuscript.

> 3\) The authors should address the unlikely but formal possibility that increased Keima signal results from slower degradation of Keima in the mutants rather than increased mitophagy.

In their original paper on Keima and mt-Keima imaging (Katayama et al., 2011) Katayama et al. convincingly demonstrate that lysosomal proteases are to degrade Keima and mt-Keima (Figure S2 in their paper). The known resistance of mt-Keima to lysosomal degradation makes it extremely unlikely that the increased lysosomal mt-Keima signal in the parkin- and PINK1-deficient flies results from slower degradation of mt-Keima in the mutant lysosomes.
